Podcasts about Comparative effectiveness research

As a follow up to the ISMPP U Digital Features – Are they really worth it? held live on June 7, 2023, join three of the faculty from the webinar as they come back together with a lively discussion of the comments and questions submitted by the audience during the live event. Listen now, even if you haven't watched the webinar, this discussion can also be a good preview! If you are interested in the original ISMPP U, please go to the ISMPP website or find the link in the description or written transcript of this podcast. The archived webinar is free to members. Our guest host today is Caroline Halford, who has 15 years with the Adis journal portfolio and has presented and published several studies on the impact of PLS and digital features. Our guests are Adeline Rosenberg, Senior Medical Writer, Patient Engagement at Oxford PharmaGenesis and co-author of the Open Pharma PLS recommendations; and Joanne Walker, co-founder of Becaris Publishing, the publisher of the open access publication Journal of Comparative Effectiveness Research and digital hub The Evidence Base.

Congress inches closer to a massive, 725-page spending bill referred to as “Reconciliation.” It includes several drug pricing provisions that claim to lower Rx costs for seniors. But a closer look reveals that those savings aren't as widespread as patients might expect.Terry and Dr. Bob recruit the help of Medicare policy expert Doug Badger to uncover the top facts about the bill that patients need to know. Plus, hear from Michael Riotto, a multiple myeloma warrior who recaps his experience at the We the Patients Fly-In, including health policies that directly impact his ability to access care. And correspondent Jess Wofford of Pittsburgh gives her perspective as a nurse and patient on PBM practices that hurt access to affordable care. Hosts: Terry Wilcox, Executive Director, Patients RisingDr. Robert Goldberg, “Dr. Bob,” Co-Founder and Vice President of the Center for Medicine in the Public InterestKate Pecora, Field Correspondent Guests:Doug Badger, Senior Research Fellow, The Heritage Foundation and The Galen InstituteMichael Riotto, Multiple Myeloma Journey Partner, HealthTreeJess Wofford, Patient CorrespondentLinks: Apply Today! Advocacy Masterclass RxRelief4AllWatch: Multiple Myeloma Advocate Michael Riotto in DC for We the Patients Fly-InThe Impact of HR5376 on Biopharmaceutical Innovation and Patient Health CBO Cost Estimate: Reconciliation Recommendations for Prescription Drug LegislationJohn Vernon, Fewer Drugs, Shorter Lives, Less Prosperity: The Impact of Comparative Effectiveness Research on Health and WealthThe Financial Burden of PBM Benefit Design on People Using Specialty MedicinesIt's Time to Expose the Secret Drug Scam at the Heart of American Health CarePatients Rising Concierge Need help?The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.orgHave a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent?Drop us a line: podcast@patientsrising.orgThe views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising.

Lead author, Dr. Klaus Witte, Senior Lecturer and Consultant Cardiologist, University of Leeds and Leeds General Infirmary, discusses findings from a new economic study titled "Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke". Results were recently published in the Journal of Comparative Effectiveness Research. Klaus Witte is a Senior Lecturer and Consultant Cardiologist in the Leeds Institute of Cardiovascular and Metabolic Medicine at the University of Leeds. He has his own group investigating the relationship between pacemaker therapy and heart failure and also is the Head of the Department of Clinical and Population Science in the Leeds Institute of Cardiovascular and Metabolic Medicine with line management responsibilities for over 40 investigators, fellows and technical staff. His research interests include vitamin D in CHF, and he was principle investigator of VINDICATE, the largest study of vitamin D supplementation in CHF patients (Medical Research Council) showing improved LV function following one year of vitamin D. He was co-investigator on the recently published REM-HF study (Eur Heart J) describing a neutral effect of remote monitoring in CHF patients (British Heart Foundation). He is the only cardiologist in the UK to have held an NIHR (UK) clinician scientist award, in his case for the OPT-pace project, which, with 1800 patients enrolled is the largest ever prospective study to collect information on the relationship between pacemakers and heart failure (EHRA late breaking clinical trials 2019). He has recently published the results of the REDUCE-FMR study describing the potential of a transvenous coronary sinus-based approach to reducing mitral regurgitation in patients with heart failure and reduced ejection fraction (JACC-HF) He has long questioned standard teaching around heart rate and exercise capacity in heart failure (JACC 2016). His group described a reproducible non-invasive technique to measure contractility and plot the force-frequency relationship. Peak contractility in heart failure occurs at a lower heart rate than in health. This finding and two randomised double-blind clinical trials describing the benefit on exercise capacity of programming pacemakers using patients’ force frequency relationship information (JACC-HF 2018, Circulation 2020) have changed the way we view heart rate in heart failure. His interests extend to health economics, specifically the assessment of cost effectiveness of device therapy, where the upfront costs of devices in a population are particularly challenging for payers.

If you want to better understand what comparative effectiveness research is and how it could be used to influence formularies, then this episode is for YOU! During this episode, you'll learn the following: What misaligned incentives are currently in place in the market that do not help to lower cost of medications What Comparative Effectiveness Research is and the organizations that publish it How Comparative Effectiveness Research is used by TruData to create our algorithms. With this information and the cost data, a formulary, benefits plan design can be made on clinical data not just brand to generic or what rebates are largest for the PBM. What roles that a pharmacist can excel at How to look for pharmacy type roles that do not fall into the retail/hospital space Guest - Greg Snyder, PharmD, MBA https://www.linkedin.com/in/snydergregory/ https://www.linkedin.com/company/trudatarx/ https://www.trudatarx.com https://tedxbeaconstreet.com/videos/whats-the-prescription-for-lowering-drug-prices/ TEDx talk given by TruData CEO, Catalina Gorla Host - Hillary Blackburn, PharmD www.pharmacyadvisory.com https://www.linkedin.com/in/hillary-blackburn-67a92421/ @talktoyourpharmacist for Instagram and Facebook @HillBlackburn Twitter★ Support this podcast on Patreon ★

Dr. Jeffrey Jim is an Associate Professor of Surgery and Program Director, Vascular Surgery Fellowship and Integrated Residency at the Barnes-Jewish Hospital and Washington University in St Louis, Missouri. He takes some time to discuss the basics of TransCarotid Artery Revascularization (TCAR), comparative effectiveness research and drivers of cost in vascular surgery. Disclosures: Consultant for Silk Road Medical (Proctor, Co-Director of National Test Drive: Education courses for physicians) Consultant for Medtronic (speaker/educational content) (0:28) Academic Bio and Video Bio (4:22) TransCarotid Artery Revascularization (14:22) Updated data and publications on TCAR 1-year outcomes of ROADSTER trial Multi-Institution data observational data SVS-VQI Registry data (19:45) Long term outcomes of carotid stenting (22:00) Masters in Population Health Sciences (23:10) Cost-effectiveness analyses in Vascular Surgery (29:30) Predicting future workload and implications for training and SVS comments on vascular surgery workforce

An experienced senior executive with several years of experience in the pharmaceutical and biotechnology industry, Will has held key positions where he was instrumental in launching a variety of innovative platforms in medical affairs. He speaks frequently regarding the ever-changing role of medical affairs at most major medical affairs conferences and is currently president and CEO of the ACMA, whose primary mission is to create industry standards and goals for medical affairs professionals. Will has held key management roles across the industry within medical affairs, such as at Eisai, Retrophin, Gilead Sciences, Abbott Laboratories, Boehringer Ingelheim, and Merck. Will previously also served as vice president of medical and scientific affairs at CME LLC, a leading provider of continuing medical education to health care providers nationwide. He also has worked on the strategic management consulting side with companies such as Veeva Systems and often provides medical affairs consultancy services for Bain, McKinsey, BCG, Atheneum Partners, and Alpha Insights. He has published extensively and led a number of initiatives focusing in the areas of ischemic heart disease, dyslipidemia, diastolic heart failure, type 2 diabetes, and obesity, where he has collaborated with some of the nation's top research institutions, such as the Pennington Biomedical Research Center, the Washington Center for Weight Management & Research, the Yale School of Medicine Digestive Diseases Program, and the University of Pennsylvania's Center for Weight & Eating Disorders. Will was most recently invited to speak at the Center for Medical Technology Policy's (CMTP) conference on Comparative Effectiveness Research to help inform payers, health care policy makers, physicians, and patients on the most effective ways to design clinical trials to better address gaps in medicine. He also presented at the 2014 annual American Diabetes Association (ADA) Conference on preventing the progression of type 2 diabetes among prediabetic overweight and obese individuals. In 2008, Will published a book entitled The Rise of Chemistry: Implications for Industry and Education. He has also held several academic appointments at Seton Hall University's School of Health and Medical Sciences; New Jersey City University; Kean University's College of Natural, Applied, and Health Sciences; and Touro Colleges of Osteopathic Medicine, Pharmacy, and Physical Therapy teaching a variety of courses, including clinical therapeutics, pharmacology, pathophysiology, and epidemiology. Will has served as a board member for the MSL Institute. He is a member of several organizations, including the American College of Cardiology (ACC), the American Diabetes Association (ADA), The Obesity Society (TOS), the American Association of Clinical Endocrinology (AACE), the American Society of Bariatric Physicians (ASBP), the American Heart Association (AHA), the Drug Information Association (DIA), and the American Chemical Society (ACS). 00:00 Will's background and how he became president and CEO of the ACMA. 02:30 The difference between a sales rep and a medical science liaison (MSL). 04:35 The need for better education among medical affairs and pharma workers. 09:10 Working with key thought leaders and the Consensus Statement they are currently working on. 12:00 How accreditation courses work to help MSLs provide more of a balanced view of a pharma product. 15:50 The pressure for Pharma and manufacturers to become Outcomes Companies. 16:25 How are MSLs evolving? 17:20 “Really, what is the value of the product?” 22:00 How ACMA remains unbiased in their course curriculum. 23:15 How health care providers can verify that they are getting the clearest unbiased pharma information possible from their MSLs. 25:25 EP187 with Sandra Leal and Todd Eury, EP181 with Dr. Lipi Roy. 25:40 The state of opioid addiction in America and how pharma information contributed to the problem. 30:05 EP148 and AEE2 with Jennifer Miller. 30:25 “It's time there's a third party that's vetting what we're doing.” 32:40 You can learn more at medicalaffairsspecialist.org.

Breaking Down the BCMAS Certification: A Conversation with Dr. William Soliman of ACMA An experienced executive with several years of experience in the pharmaceutical and biotechnology industry, Dr. Soliman has held key positions within medical affairs where he was instrumental in launching a variety of innovative platforms expanding the role of medical affairs across the industry. He is currently the President of the Accreditation Council for Medical Affairs (ACMA). Dr. Soliman is often invited to speak at important pharmaceutical industry conferences focusing on medical affairs, patient navigation and its relationship to field based medical teams, and the ever-changing role of the medical science liaison (MSL). He has also held a variety of critical management roles across the industry at Eisai, Veeva, Retrophin, Gilead Sciences, Abbott Laboratories, Boehringer Ingelheim and Merck. Dr. Soliman previously also served as Vice President of Medical and Scientific Affairs at CME LLC, a leading provider of CME to health care providers nationwide. He has published extensively and led a number of initiatives focusing in the areas of ischemic heart disease, dyslipidemia, diastolic heart failure, type 2 diabetes, and obesity where he has collaborated with some of the nation's top research institutions such as the Pennington Biomedical Research Center, the Washington Center for Weight Management & Research, the Yale School of Medicine Digestive Diseases Program, and the University of Pennsylvania's Center for Weight & Eating Disorders. Dr. Soliman was most recently invited to speak at the Center for Medical Technology & Policy's (CMTP) conference on Comparative Effectiveness Research to help inform payers, healthcare policy makers, physicians and patients on the most effective ways to design clinical trials to better address gaps in medicine. He has also held several academic appointments at Seton Hall University's School of Health & Medical Sciences, New Jersey City University, Kean University's College of Natural & Applied Sciences, and Touro College of Physical Therapy & Pharmacy teaching a variety of courses including clinical therapeutics, pharmacology, pathophysiology and epidemiology. Dr. Soliman earned his Ph.D, MPHil. from Columbia University, his Bachelor's degree from New York University and a Master's Degree from St. Peter's University focused in Biochemistry & Education. He also completed post-doctoral work at Harvard University T.H. Chan School of Public Health.  William Soliman, PhD, MPhil, MA https://www.linkedin.com/in/williamsoliman1/ ACMA: https://www.medicalaffairsspecialist.org/board-certified-medical-affairs-specialist-program/ wasoliman1@gmail.com This podcast was sponsored by the ACMA. Other Pharmacy Podcast Episodes mentioned in this podcast: Breaking into the pharmaceutical industry as an MSL:   https://html5-player.libsyn.com/embed/episode/id/5508336/height/360/width/640/theme/standard/autonext/no/thumbnail/yes/autoplay/no/preload/no/no_addthis/no/direction/backward/   What is a Medical Science Liaison (MSL)?   http://html5-player.libsyn.com/embed/episode/id/4974092/height/360/width/640/theme/standard/autonext/no/thumbnail/yes/autoplay/no/preload/no/no_addthis/no/direction/backward/no-cache/true/   Certifications for pharmacists and Healthcare Professionals:   http://html5-player.libsyn.com/embed/episode/id/5007759/height/360/width/640/theme/standard/autonext/no/thumbnail/yes/autoplay/no/preload/no/no_addthis/no/direction/backward/no-cache/true/ See omnystudio.com/listener for privacy information.

15 September 2015: In this Skinpod episode, Dr. Vinod Nambudiri, Brigham and Women's Hospital, discusses his Research Techniques Made Simplearticle on comparative effectiveness research (CER), which helps clinicians identify the best strategies among a variety of available preventive, diagnostic, and treatment options for patients.

Mitch Mirkin of VA Research Communications talks with Dr. Paula Schnurr, director of VA's National Center for PTSD, about a major clinical trial now underway in VA called "Comparative Effectiveness Research in Veterans with PTSD (CERV-PTSD)." The trial is a head-to-head comparison of the two main psychotherapies VA uses to treat PTSD. The trial, sponsored by VA's Cooperative Studies Program, will involve 900 Veterans at nearly 20 VA sites. Read More: "Probing psychotherapies for PTSD"

Tue, 22 Aug 2017 06:40:10 +0000 https://evidenzbasierte-pharmazie.podigee.io/44-sonderfolge-evidenz-geschichte-n-die-cast-studien-oder-aufgepasst-bei-surrogaten f27e329e5964269c3cc662ad6cb10ffe In den 1980er Jahren wollten Ärzte Patienten nach einem Herzinfarkt etwas Gutes tun und verabreichten ihnen Antiarrhythmika. Die normalisierten den Herzrhythmus und verringerten im EKG Herzrhythmusstörungen. Leider senkten sie aber nicht wie erhofft die Sterblichkeit, sondern ließen sie sogar noch ansteigen. Die Geschichte der CAST-Studien ist ein eindrückliches Beispiel, wie gefährlich es sein kann, sich in Studien auf Surrogatendpunkte zu verlassen. Unsere Quellen Gesundheitsinformation.de: Evidenzbasierte Medizin - Können Messwerte zeigen, ob eine Behandlung hilft? Testing Treatments: Erhoffte, aber nicht eingetretene Wirkung P. Kleist: Biomarker und Surrogat-Endpunkte: Garanten für eine schnellere Zulassung von neuen Arzneimitteln? Schweizerische Ärztezeitung 2002; 83: 44ff. H.C. Bucher: Studien mit Surrogatendpunkten. Nutzen und Grenzen in der klinischen Entscheidungsfindung. Internist 2008; 49:681–687 Vorläufiger Bericht der CAST-Studie Ausführlicher Bericht zu CAST-I Bericht zu CAST-II Bigger JT. The events surrounding the removal of encainide and flecainide from the Cardiac Arrhythmia Suppression Trial (CAST) and why CAST is continuing with moricizine. J Am Coll Cardiol 1990 Jan;15(1):243-5. Hampton J. Therapeutic fashion and publication bias: the case of anti-arrhythmic drugs in heart attack. James Lind Library 2015 Lauer M et al. Epidemiology, Comparative Effectiveness Research, and the NIH: Forces for Health. Epidemiology 2011 Sep; 22(5): 625–628. 44 full no Dr. Ir

ACMA Board Certified Medical Affairs Specialist Program (BCMAS) Certification – Q&A with Dr. William Soliman - Chair – Accreditation Council for Medical Affairs   An experienced executive with several years of experience in the pharmaceutical and biotechnology industry, Dr. Soliman has held key positions within medical affairs where he was instrumental in launching a variety of innovative platforms expanding the role of medical affairs across the industry. He is currently the Chair of the Accreditation Council for Medical Affairs (ACMA). Dr. Soliman is often invited to speak at important pharmaceutical industry conferences focusing on medical affairs, patient navigation and its relationship to field based medical teams, and the ever-changing role of the medical science liaison (MSL). He has also held a variety of critical management roles across the industry at Eisai, Veeva, Retrophin, Gilead Sciences, Abbott Laboratories, Boehringer Ingelheim and Merck. Dr. Soliman previously also served as Vice President of Medical and Scientific Affairs at CME LLC, a leading provider of CME to health care providers nationwide. He has published extensively and led a number of initiatives focusing in the areas of ischemic heart disease, dyslipidemia, diastolic heart failure, type 2 diabetes, and obesity where he has collaborated with some of the nation's top research institutions such as the Pennington Biomedical Research Center, the Washington Center for Weight Management & Research, the Yale School of Medicine Digestive Diseases Program, and the University of Pennsylvania's Center for Weight & Eating Disorders. Dr. Soliman was most recently invited to speak at the Center for Medical Technology & Policy's (CMTP) conference on Comparative Effectiveness Research to help inform payers, healthcare policy makers, physicians and patients on the most effective ways to design clinical trials to better address gaps in medicine. He has also held several academic appointments at Seton Hall University's School of Health & Medical Sciences, New Jersey City University, Kean University's College of Natural & Applied Sciences, and Touro College of Physical Therapy & Pharmacy teaching a variety of courses including clinical therapeutics, pharmacology, pathophysiology and epidemiology. Dr. Soliman earned his Ph.D, MPHil. from Columbia University, his Bachelor's degree from New York University and a Master's Degree from St. Peter's University focused in Biochemistry & Education. He also completed post-doctoral work at Harvard University T.H. Chan School of Public Health.  William Soliman, PhD, MPhil, MA https://www.linkedin.com/in/williamsoliman1/ ACMA: https://www.medicalaffairsspecialist.org/board-certified-medical-affairs-specialist-program/ wasoliman1@gmail.com Anne Leighty – P4 pharmacy major: https://www.linkedin.com/in/anneleighty/ This podcast was sponsored by the ACMA. See omnystudio.com/listener for privacy information.

In a new article for the Journal of Comparative Effectiveness Research, experts from Mathematica Policy Research reveal why some patients might reject physician recommendations even if they are grounded in good evidence. Listen to Mathematica researchers Cara Stepanczuk and Nyna Williams discuss this issue in this episode of the “Policy in Perspective” podcast.

Dr. Simpson is the president and chief executive officer of AcademyHealth. A nationally recognized health policy researcher and pediatrician, she is a passionate advocate for the translation of research into policy and practice. Her research focused on improving the performance of the health care system and included studies of the quality and safety of care, health and health care disparities and the health policy and system response to childhood obesity. Before joining AcademyHealth, Dr. Simpson was director of the Child Policy Research Center at Cincinnati Children's Hospital Medical Center and professor of pediatrics in the Division of Health Policy and Clinical Effectiveness, Department of Pediatrics, University of Cincinnati. She served as the Deputy Director of the Agency for Healthcare Research and Quality from 1996 to 2002. Dr. Simpson serves on the Robert Wood Johnson Clinical Scholars Program National Advisory Council, and the Editorial boards for the Journal of Comparative Effectiveness Research and Frontiers in Public Health Systems and Services Research. Dr. Simpson earned her undergraduate and medical degrees at Trinity College (Dublin, Ireland), a master's in public health at the University of Hawaii, and completed a post-doctoral fellowship in health services research and health policy at the University of California, San Francisco. She was awarded an honorary Doctor of Science degree by the Georgetown University School of Nursing and Health Studies in 2013. 00:00 What Academy Health is.00:45 How Academy Health improves the health system by using health evidence to inform current health policy decision makers.04:00 How Academy Health helps organizations learn from each other.07:40 “What are we learning from the research?”09:00 “The decisions will be made, and our goal is to bring evidence into that decision-making process.”14:45 “The reality is that it's not one or the other, it's a continuum in between.”16:00 A continuum of research between explanation and intervention.16:30 “What works, and at what cost?”22:20 The three counsels at Academy Health: Education, Methods, and Measurements.24:00 The 19 different themes happening at Academy Health's annual meeting in Boston.27:30 Academy Health's partnership with the Annual Health Datapalooza.28:00 “Data Liberation and Data Application.”30:00 The “tsunami of data available” at the Annual Health Datapalooza.34:00 You can find out more information at www.academyhealth.org or by emailing Lisa at lisa.simpson@academyhealth.org.

Drs. Hirsch, Meyers and Jayaraman discuss the evolving and at times complex role of Evidence Based Medicine (EBM) in contemporary neurointerventional practice. The discussants contrast EBM with Comparative Effectiveness Research and the role it plays in coverage decisions.The podcast directly links to the following articles: http://www.ncbi.nlm.nih.gov/pubmed/24578482?dopt=AbstractGeneral considerations:http://www.ncbi.nlm.nih.gov/pubmed/22166819http://jnis.bmj.com/content/4/1/11.longWhy standards:http://www.ncbi.nlm.nih.gov/pubmed/21994097http://jnis.bmj.com/content/1/1/5.long

Dr. Christopher Slatore interviews Dr. Jerry Krishnan about the ATS Research Statement on Comparative Effectiveness Research

If you experience any technical difficulties with this video or would like to make an accessibility-related request, please send a message to digicomm@uchicago.edu. The fourth session of Equity and Choice in Health Care Access, a conference in celebration of the 50th anniversary of the Center for Health Administration Studies (CHAS) at the University of Chicago School of Social Service Administration, was entitled, “System Transformation and the ACA“ and included two speakers and a respondent. The first speaker was Eric Patashnik. His talk focused on the surprisingly weak evidence-based approach of American medicine and how the Comparative Effectiveness Research project, part of the Affordable Care Act, is working to correct this. Bio: http://batten.virginia.edu/content/faculty-research/faculty/eric-m-patashnik

If you experience any technical difficulties with this video or would like to make an accessibility-related request, please send a message to digicomm@uchicago.edu. The fourth session of Equity and Choice in Health Care Access, a conference in celebration of the 50th anniversary of the Center for Health Administration Studies (CHAS) at the University of Chicago School of Social Service Administration, was entitled, “System Transformation and the ACA“ and included two speakers and a respondent. The first speaker was Eric Patashnik. His talk focused on the surprisingly weak evidence-based approach of American medicine and how the Comparative Effectiveness Research project, part of the Affordable Care Act, is working to correct this. Bio: http://batten.virginia.edu/content/faculty-research/faculty/eric-m-patashnik

CYCORE (Cyberinfrastructure for Comparative Effectiveness Research) was a clinical trial conducted by The University of Texas MD Anderson Cancer Center, University of California-San Diego and University of Alabama at Birmingham, that studied the use of sensing devices to wirelessly send health-related data from the patient’s home to the cancer research facility. The purpose of this study is for other researchers to use CYCORE’s technology to gather more detailed information in their own clinical trials. Susan Peterson, Ph.D., M.P.H., lead investigator on the study and associate professor in the Department of Behavioral Science at MD Anderson, discusses the results.

Many would agree that healthcare delivery today is inefficient, ineffective, and segmented. In this panel discussion, experts talk about how they have persisted in delivering high-quality treatment. They discuss innovations in redesigning and scaling operations for wider benefit, the realities of implementation, and the need to train clinical workers in delivering compassionate care. The discussion was part of the 2011 Healthcare Summit, held at the Stanford Graduate School of Business. Gerald (Jerry) Coil is special assistant to the CMO, AltaMed Health Services. He has served as an internal consultant at AltaMed; senior consultant at Cattaneo & Stroud, Inc.; executive vice president and COO at HealthSpring; president and CEO at MHN; senior vice president at Health Net; senior vice president, benefit administration, at Kaiser Permanente; partner at NorthShore LLC; and regional vice president, Pacific Rim at North American Medical Management/Phycor. Thomas Lee is an MD with One Medical Group. He specializes in primary care internal medicine with an emphasis on preventive health, complex cases and quality improvement. Lee graduated from Yale University and the University of Washington School of Medicine, and completed his residency at Harvard’s Brigham and Women’s Hospital before serving as editor-in-chief for the widely used drug reference application Epocrates. He then founded One Medical Group as a step toward improving primary care delivery. Paul Wallace is director of the Lewin Center for Comparative Effectiveness Research. A board certified physician in internal medicine and hematology, he is a renowned lecturer on topics including evidence-based medicine practice and policy; performance improvement and measurement; clinical practice guideline development; population-based care and disease management; new technology assessment; and comparative assessment. He serves on advisory committees at the Institute of Medicine (IOM), and is a member of a number of healthcare-related boards. Arnold Milstein is professor of medicine and leader of Stanford University’s Clinical Excellence Research Center. His career and ongoing research are focused on acceleration of clinical service innovations that improve the societal value of health care. He serves as the medical director of the Pacific Business Group on Health, the largest regional health care improvement coalition in the U.S. He also guides employer-sponsored clinically-based innovation development for Mercer Health and Benefits. Previously he co-founded the Leapfrog Group and Consumer-Purchaser Disclosure Project, and served as a Congressionally-appointed MedPAC Commissioner. https://ssir.org/podcasts/entry/service_innovation

Eugene Rich of Mathematica Policy Institute discusses CER.

Eugene Rich of Mathematica Policy Institute discusses CER.

Eugene Rich of Mathematica Policy Institute discusses CER.

Eugene Rich of Mathematica Policy Institute discusses CER.

Radiographic imaging: evaluating its benefits and consequences; excerpts from presentations by William Black, MD, of Dartmouth Hitchcock Medical Center, and Peter Bach, MD, MAPP, of Memorial Sloan Kettering Cancer Center, from a recent conference on Methodological Challenges in Comparative Effectiveness Research; plus a summary of all articles in the issue.

Host: Janet Wright, MD Guest: Mark Hlatky, MD Implantable cardioverter defibrillators, or ICDs, can be life saving for patients after myocardial infarction, but are also costly and may not be appropriate for all of the hundreds of thousands of patients who have had MI. Which subsets of patients might benefit most from ICDs, and might prophylactic use of ICDs early after MI reduce the risk of cardiac death? Dr. Mark Hlatky, professor of medicine and professor of health research and policy at Stanford University School of Medicine, weighs the comparative-effectiveness research on the efficacy of ICDs for patients early after MI, versus waiting a few months before implanting ICDs or trying other forms of therapy. Outside of implantable devices, what else can physicians do to reduce the risk of death after MI? Hosted by Dr. Janet Wright. Produced in Cooperation with

Host: Janet Wright, MD Guest: Mark Hlatky, MD Implantable cardioverter defibrillators, or ICDs, can be life saving for patients after myocardial infarction, but are also costly and may not be appropriate for all of the hundreds of thousands of patients who have had MI. Which subsets of patients might benefit most from ICDs, and might prophylactic use of ICDs early after MI reduce the risk of cardiac death? Dr. Mark Hlatky, professor of medicine and professor of health research and policy at Stanford University School of Medicine, weighs the comparative-effectiveness research on the efficacy of ICDs for patients early after MI, versus waiting a few months before implanting ICDs or trying other forms of therapy. Outside of implantable devices, what else can physicians do to reduce the risk of death after MI? Hosted by Dr. Janet Wright. Produced in Cooperation with

Enhanced Video PodcastAired date: 2/16/2010 1:00:00 PM Eastern Time

Enhanced Audio PodcastAired date: 2/16/2010 1:00:00 PM Eastern Time

Guest: Sean Tunis, MD, MSc Host: Jack Lewin, MD The Institute of Medicine recently released a list of 100 priority topics for comparative effectiveness research. The first topic on the first page of the report calls for an evaluation of treatment strategies for atrial fibrillation, from surgery or catheter ablation, to pharmacologic therapy. How do we design research to produce an accurate comparison of these treatment options, and what other subjects should stand at the top of our priority list? Dr. Sean Tunis shares his perspective on these questions with host Dr. Jack Lewin. Dr. Tunis, the founding director of the Center for Medical Technology Policy in Baltimore and formerly the director of the Office of Clinical Standards and Quality and chief medical officer for the Centers for Medicare and Medicaid Services, says it may not be the spotless level 1 data that proves ideal for improving our evidence base, but rather a broader range of imperfect information that can be shaped for our clinical benefit.

Guest: Sean Tunis, MD, MSc Host: Jack Lewin, MD The Institute of Medicine recently released a list of 100 priority topics for comparative effectiveness research. The first topic on the first page of the report calls for an evaluation of treatment strategies for atrial fibrillation, from surgery or catheter ablation, to pharmacologic therapy. How do we design research to produce an accurate comparison of these treatment options, and what other subjects should stand at the top of our priority list? Dr. Sean Tunis shares his perspective on these questions with host Dr. Jack Lewin. Dr. Tunis, the founding director of the Center for Medical Technology Policy in Baltimore and formerly the director of the Office of Clinical Standards and Quality and chief medical officer for the Centers for Medicare and Medicaid Services, says it may not be the spotless level 1 data that proves ideal for improving our evidence base, but rather a broader range of imperfect information that can be shaped for our clinical benefit.

--{ Logic Estranged for the Deranged: "Soya, Veggies and Beans, the Farce is Starting, We'll Soon, by Law, Each Pay for Farting, A Collective Punishment on the Masses For Expelling Legume Greenhouse Gases, A Whole Lot of Nothing to be Traded for Money, Two Cons Together, Now ain't that Funny, No Jobs, and Services Given the Axe As We're Ordered to Pay Existence Tax, We're Bankrupt, Soon to Ration Food, Sending Billions to Third World for 'Common Good' " © Alan Watt }-- Media Spins - Legal Declarations, Agreement by Silence - "Voluntary" becomes Mandatory, Driving Licences, Auto Insurance - Personal Carbon Tax, Carbon Offset for Air Travel - Chicago Climate Exchange (Casino); Contracts, Permits and Penalties for Energy Consumption - Al Gore Socialized (Factory) Medicine, Cutting Costs - Obama, "Burden of Elderly", Euthanasia - Flu Shots for U.S. - Mix of Common Flu and Avian Flu, Viral Mutations from Hosts' DNA, Breeding Viruses - Contagious Diseases - Creation of Killer Virus (Spanish Flu Mix) - Swine Flu Diagnosis and Hype. Svalbard, Norway's Global Seed Storage Bank. PBSG Polar Bear Conference, Dr. Taylor's "Contrary Belief" on Global Warming, More Bears (They Can Swim), Thickening Arctic Ice. WWF wants Vegetarian World, Meat and Dairy Warning Labels - War Scenario to Unite Planet - Food Rationing - Foundation-Funded NGOs, Soviet Rule by Councils - Gordon Brown's Call for New Bretton Woods. Creation of Communism by Bankers - World Population Reduction and Management. (Articles: ["Zerofootprint" [Voluntary Personal Carbon Offset Tax] (zerofootprint.net).] ["Your Personal Climate Exchange" by Ian Ayres and Barry Nalebuff (forbes.com) - Nov. 24, 2008.] ["Listening Session of the Federal Coordinating Council for Comparative Effectiveness Research" (hhs.gov) - June 10, 2009.] ["Comparative Effectiveness Research Funding" (hhs.gov).] ["Federal Coordinating Council for Comparative Effectiveness Research" [PDF File] (hhs.gov) - June 30, 2009.] [Video: "Obama Depopulation Policy Exposed!" [See Obama's Top Man Emanuel Leave Quickly When His Pro-Euthanasia Policy is Exposed] (youtube.com).] [Video: "Obama Admin to Depopulate This Fall 2009" [US to get 3 flu Shots by Law] (youtube.com).] ["US VIPs to visit Svalbard's Global Seed Bank" by A. Rienstra (icenews.is) - July 20, 2008.] ["Polar bear expert barred by global warmists" by Christopher Booker (telegraph.co.uk) - June 27, 2009.] ["Brown facing revolt over plans to raid health, transport and education budgets to pay for latest round of spending" by James Chapman (dailymail.co.uk) - July 1, 2009.] ["Eat red meat just three times a week, says World Wildlife Fund" by Sean Poulter (dailymail.co.uk) - June 29, 2009.] ["Commonwealth say IMF, UN 'inadequate' on crises" Reuters (polity.org.za) - June 10, 2008.]) *Title/Poem and Dialogue Copyrighted Alan Watt - June 30, 2009 (Exempting Music, Literary Quotes, and Callers' Comments)

Randy Stafford, MD, PhD, discusses comparative effectiveness research and its role in health-care reform. (June 15, 2009)

See acast.com/privacy for privacy and opt-out information.